AbbVie Inc. $ABBV Stock Holdings Increased by Summit Global Investments

Summit Global Investments lifted its stake in AbbVie Inc. (NYSE:ABBV) by 45.1% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 16,792 shares of the company’s stock after purchasing an additional 5,220 shares during the quarter. Summit Global Investments’ holdings in AbbVie were worth $4,393,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in ABBV. Corient Private Wealth LP purchased a new stake in AbbVie in the 2nd quarter worth approximately $559,736,000. Legal & General Group Plc bought a new stake in AbbVie during the 2nd quarter worth approximately $2,905,952,000. Jupiter Topco LLC bought a new stake in AbbVie during the 2nd quarter worth approximately $1,560,354,000. Canada Pension Plan Investment Board bought a new stake in AbbVie during the 2nd quarter worth approximately $817,473,000. Finally, The Manufacturers Life Insurance Company purchased a new position in AbbVie during the second quarter valued at approximately $655,268,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Trading Up 1.4%

Shares of ABBV opened at $294.80 on Friday. The business’s 50 day moving average is $269.35 and its 200 day moving average is $237.23. The company has a market capitalization of $520.85 billion, a PE ratio of 50.74, a price-to-earnings-growth ratio of 1.35 and a beta of 0.24. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $298.74.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. During the same period in the previous year, the firm earned $1.86 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. Equities research analysts predict that AbbVie Inc. will post 13.92 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.3%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. BNP Paribas Exane upped their price target on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Citigroup raised their price objective on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. UBS Group raised their price objective on shares of AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a research report on Tuesday, October 6th. Barclays lifted their target price on shares of AbbVie from $300.00 to $325.00 and gave the company an “overweight” rating in a research note on Wednesday, October 21st. Finally, Morgan Stanley upped their target price on shares of AbbVie from $296.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $279.86.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.